Raloxifene fares as well as tamoxifen in 2 related comparison studies

被引：0
|
作者：
不详
机构：
来源：
FORMULARY | 2006年 / 41卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：466 / +
页数：2
相关论文
共 50 条
  • [1] The effects of tamoxifen versus raloxifene on the risk of developing noninvasive breast cancer in the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial.
    Vogel, V. G.
    Costantino, J. P.
    Wickerham, D. L.
    Wolmark, N.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S16 - S16
  • [2] Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes - The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial
    Vogel, Victor G.
    Costantino, Joseph P.
    Wickerham, D. Lawrence
    Cronin, Walter M.
    Cecchini, Reena S.
    Atkins, James N.
    Bevers, Therese B.
    Fehrenbacher, Louis
    Pajon, Eduardo R., Jr.
    Wade, James L., III
    Robidoux, Andre
    Margolese, Richard G.
    James, Joan
    Lippman, Scott M.
    Runowicz, Carolyn D.
    Ganz, Patricia A.
    Reis, Steven E.
    McCaskill-Stevens, Worta
    Ford, Leslie G.
    Jordan, V. Craig
    Wolmark, Norman
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (23): : 2727 - 2741
  • [3] 2X4 HOUSING FARES WELL IN KOBE QUAKE
    COWAN, F
    FORESTRY CHRONICLE, 1995, 71 (03): : 343 - 344
  • [4] Ab initio studies of tamoxifen and related compounds
    Huang, MJ
    INTERNATIONAL JOURNAL OF QUANTUM CHEMISTRY, 2004, 96 (04) : 374 - 379
  • [5] Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention - The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial
    Land, Stephanie R.
    Wickerham, D. Lawrence
    Costantino, Joseph P.
    Ritter, Marcie W.
    Vogel, Victor G.
    Lee, Myoungkeun
    Pajon, Eduardo R.
    Wade, James L., III
    Dakhil, Shaker
    Lockhart, James B., Jr.
    Wolmark, Norman
    Ganz, Patricia A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (23): : 2742 - 2751
  • [6] Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial (vol 295, pg 2727, 2006)
    Vogel, V. G.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24): : 2926 - 2926
  • [7] THE ANTIOXIDANT ACTION OF KETOCONAZOLE AND RELATED AZOLES - COMPARISON WITH TAMOXIFEN AND CHOLESTEROL
    WISEMAN, H
    SMITH, C
    ARNSTEIN, HRV
    HALLIWELL, B
    CANNON, M
    CHEMICO-BIOLOGICAL INTERACTIONS, 1991, 79 (02) : 229 - 243
  • [8] Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial (vol 295, pg 2727, 2006)
    Vogel, V. G.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (09): : 973 - 973
  • [9] Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial (vol 295, pg 2742, 2006)
    Land, S. R.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (09): : 973 - 973
  • [10] A COMPARISON OF 2 AND 3 YEARS OF ADJUVANT TAMOXIFEN
    WOLMARK, N
    REDMOND, C
    FISHER, B
    HORMONE RESEARCH, 1989, 32 : 166 - 168
12345